Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers.
Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments.
The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
The Board of Directors of Nanologica AB (publ) (“Nanologica” or the “Company”) unanimously recommends the shareholders of Nanologica not to accept the mandatory cash offer made by Flerie Invest AB (“Flerie”) on May 23, 2025. This statement is made by the Board of Directors of Nanologica in accordance with section II.19 of the Takeover Rules
Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a new customer in the US. The customer is a manufacturer of peptide drugs, and the order relates to evaluation of NLAB Saga® on a production scale. This is Nanologica’s first order in the North American market for evaluation of the
Nanologica AB’s (publ) (“Nanologica”) main owner Flerie Invest AB (“Flerie”) has today, May 23, 2025, made a mandatory cash offer of SEK 1.00 per share to the shareholders of Nanologica (the “Offer”). The offer is made in accordance with the rules on mandatory bid due to the acquisition of additional shares in Nanologica by Flerie
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
For more videos presentations of the company and of interim reports, please refer to Investor Relations.
Company presentation made by CEO Andreas Bhagwani in June, 2023.
Investor Pitch Deck November 2024.
Please contact us at ir@nanologica.com for more information.
